Chemical synthesis, inhibitory activity and molecular mechanism of 1-deoxynojirimycin-chrysin as a potent α-glucosidase inhibitor.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
29 Nov 2021
29 Nov 2021
Historique:
received:
20
10
2021
accepted:
17
11
2021
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Hyperglycemia can be efficaciously regulated by inhibiting α-glucosidase activity and this is regarded as an effective strategy to treat type 2 diabetes. 1-Deoxynojimycin, an α-glucosidase inhibitor, can penetrate cells rapidly to potently inhibit α-glucosidase in a competitive manner. However, the application of 1-deoxynojimycin is limited by its poor lipophilicity and low bioavailability. Herein, three 1-deoxynojimycin derivatives 4-6 were designed and synthesized by linking 1-deoxynojimycin and chrysin to ameliorate the limitations of 1-deoxynojimycin. Among them, compound 6, a conjugate of 1-deoxynojimycin and chrysin linked by an undecane chain, could better bind to the α-glucosidase catalytic site, thereby exhibiting excellent α-glucosidase inhibitory activity (IC
Identifiants
pubmed: 35493254
doi: 10.1039/d1ra07753h
pii: d1ra07753h
pmc: PMC9044198
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38703-38711Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
The authors declare no competing financial interests.
Références
Food Chem Toxicol. 2020 Nov;145:111738
pubmed: 32916220
Phytochemistry. 2018 Jan;145:187-196
pubmed: 29161583
Int J Environ Res Public Health. 2016 Mar 18;13(3):
pubmed: 26999183
Bioorg Med Chem Lett. 2017 Sep 15;27(18):4309-4313
pubmed: 28838691
Int J Biol Macromol. 2019 Feb 1;122:1244-1252
pubmed: 30227201
J Clin Biochem Nutr. 2017 Jul;61(1):47-52
pubmed: 28751809
Can J Physiol Pharmacol. 2016 Apr;94(4):388-93
pubmed: 26863330
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Apr 5;176:183-188
pubmed: 28095360
Bioorg Med Chem Lett. 2017 Jul 1;27(13):2957-2961
pubmed: 28506754
Int J Pharm. 2021 Jan 5;592:120044
pubmed: 33157212
Bioorg Med Chem Lett. 2006 Jan 1;16(1):221-4
pubmed: 16213726
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2021 Nov;38(11):1840-1852
pubmed: 34266375
Pharmacol Res. 2020 Sep;159:104988
pubmed: 32504833
J Nat Prod. 2021 May 28;84(5):1534-1543
pubmed: 33979163
Eur J Med Chem. 2010 Jun;45(6):2606-12
pubmed: 20346546
Bioorg Med Chem. 2005 Mar 1;13(5):1661-71
pubmed: 15698784
Adv Synth Catal. 2016 Jun 30;358(13):2156-2162
pubmed: 28070178
Appl Microbiol Biotechnol. 2019 Dec;103(23-24):9335-9344
pubmed: 31713668
Bioorg Med Chem Lett. 1999 Mar 22;9(6):869-74
pubmed: 10206552
Curr Med Chem. 2021;28(3):628-643
pubmed: 31942844
J Biochem Mol Toxicol. 2017 Nov;31(11):
pubmed: 28682524
Appl Microbiol Biotechnol. 2004 Feb;63(6):613-25
pubmed: 14669056
Pharmacogn Rev. 2011 Jan;5(9):19-29
pubmed: 22096315
Biosci Biotechnol Biochem. 2002 Jul;66(7):1552-4
pubmed: 12224640
Bioorg Med Chem. 2009 Sep 1;17(17):6264-9
pubmed: 19664929
Toxicol Lett. 2015 Mar 4;233(2):214-25
pubmed: 25596314
Bioorg Med Chem. 2017 Jan 15;25(2):773-778
pubmed: 27956035
Planta Med. 2015 Aug;81(12-13):975-94
pubmed: 26132858
J Inorg Biochem. 2011 May;105(5):645-51
pubmed: 21450267
Exp Clin Endocrinol Diabetes. 2016 May;124(5):263-75
pubmed: 27219686
Int J Biol Macromol. 2019 Dec 1;141:358-368
pubmed: 31491512
Bioorg Med Chem. 2008 Jun 15;16(12):6333-7
pubmed: 18504133
Epilepsia. 2020 Aug;61(8):1543-1552
pubmed: 32614073
Food Chem. 2019 Nov 30;299:125102
pubmed: 31279126
Molecules. 2017 Dec 28;23(1):
pubmed: 29283418